Question 1

Who are the top researchers at Luisenkrankenhaus?

Accepted Answer

Ranked on the quality score, Mahdi Rezai, Maren Darsow and Karel Dohnal lead among researchers whose main affiliation is Luisenkrankenhaus.

Question 2

What are the most cited papers from Luisenkrankenhaus?

Accepted Answer

The most cited paper from Luisenkrankenhaus is "Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial" (Gϋnter von Minckwitz et al., 2014), with 1,048 citations. Next come "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study" (714) and "Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial" (594).

Question 3

Which research topics does Luisenkrankenhaus publish most on?

Accepted Answer

By volume in 2022-now: Schizophrenia research and treatment, Chemotherapy-related skin toxicity, Cancer Treatment and Pharmacology and Personality Disorders and Psychopathology.

Question 4

Which keywords describe research at Luisenkrankenhaus?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Radiotherapy, Quality of Life, Complications, Gene Expression, Molecular Subtypes, Clinical Practice Guidelines, Neoadjuvant Therapy and Prognostic Markers.

Question 5

Which fields of science does Luisenkrankenhaus work in?

Accepted Answer

In all years, 59% of research at Luisenkrankenhaus is in Health Sciences, 20% in Social Sciences. Its largest fields are Medicine (54%), Biochemistry, Genetics and Molecular Biology (12%), Arts and Humanities (8%). It does 2.4× the world's share of Health Sciences.

Question 6

Is Luisenkrankenhaus's research output growing?

Accepted Answer

Output in 2022-2025 was 87% lower than in 2018-2021.